Browse 6 Gruv blog articles tagged Tax Incentive. Coverage includes Tax Residency & Compliance. Practical guides, examples, and checklists for cross-border payments, tax, compliance, invoicing, and global operations.
Your client claims CIR, not you. Your job is to make sure your work can be treated as qualifying R&D. Your invoice should map cleanly to that scope, and the approval requirement should be met when subcontracted research is involved.
Treat **Opportunity Zone real estate** as a conditional tax incentive, not an automatic green light. Use this guide to make a go/no-go decision in one sitting based on your risk tolerance, tax profile, and ability to handle the compliance work.
Use this guide as a go-or-no-go compliance filter, not a shortcut. It is for globally mobile freelancers and consultants who want a practical way to decide before committing to a Greece tax-residency path.
You are managing two risks at once: building the company and protecting your personal tax outcome. With QSBS, that means running an evidence and review process from day one, not doing a one-time check and hoping it holds until exit.
As a founder, you're building for the future while managing compliance risk in the present. The R&D tax credit is a common pressure point. It can be a meaningful source of non-dilutive cash, but it also comes with complex IRS rules and real documentation demands. Many startups hesitate to claim it because the rules feel unclear, the records are thin, or the audit risk is hard to judge. That often leaves you stuck on the same question: is the savings worth the risk?
Treat this as a managed compliance asset, not a payroll perk. Official pages now refer to the expat scheme, formerly the 30% ruling. The key operational change is that from 1 January 2025 you can no longer elect partial foreign tax liability in your return. Transition relief still runs through 2026 for some people who were already using the scheme before 2024. That makes your cohort, filing timing, and asset profile worth checking early.